RAS野生型转移性结直肠癌mFOLFOXIRI联合帕尼单抗与FOLFOXIRI的生活质量对比
VOLFI(AIO-KRK 0109)II期随机试验的预设二次分析,比较mFOLFOXIRI联合帕尼单抗与FOLFOXIRI一线治疗RAS野生型转移性结直肠癌的生活质量。采用EORTC QLQ-C30在基线及治疗6、12、18、24周和治疗结束时评估,可评估77例。两臂总体生活质量及具体维度在基线和治疗12周后均无统计学显著差异。
要点
- 两臂总体生活质量及具体维度在基线和治疗12周后均无显著差异。
- 帕尼单抗组疼痛评分数值上变差、社会功能改善,但未达统计学显著。
- 发生皮肤毒性的患者中,总体生活质量与皮肤毒性分级无关。
核心结论
- mFOLFOXIRI联合帕尼单抗一线治疗RAS野生型转移性结直肠癌有效,且未对健康相关生活质量产生负面影响。
- 是否联合EGFR抗体应主要基于患者体能是否适合三药化疗,其次才考虑生活质量顾虑。
研究设计与样本
- II期随机VOLFI(AIO-KRK 0109)试验的预设二次分析,按2:1随机分配至mFOLFOXIRI联合帕尼单抗组与FOLFOXIRI组。
- 共105例随机(mFOLFOXIRI联合帕尼单抗组与FOLFOXIRI组分别63例和33例纳入意向治疗人群),77例可进行生活质量评估(分别为51例和26例)。
- 使用EORTC QLQ-C30问卷,在基线及治疗6、12、18、24周和治疗结束时评估生活质量。
主要发现
- 两臂总体生活质量及具体生活质量维度在基线和治疗12周后均无统计学显著差异。
- 接受mFOLFOXIRI联合帕尼单抗的患者在治疗期间疼痛评分数值上变差、社会功能改善。
- 在接受mFOLFOXIRI联合帕尼单抗且发生皮肤毒性的患者中,总体生活质量与皮肤毒性分级无关。
临床怎么用
- mFOLFOXIRI联合帕尼单抗可作为RAS野生型转移性结直肠癌一线选择,无需因生活质量顾虑而回避。
- 治疗决策应优先评估患者体能能否耐受三药化疗。
- 治疗期间应关注疼痛症状变化及皮肤毒性管理。
局限性
- 为II期试验的二次分析,生活质量可评估样本量有限(77例)。
- 部分生活质量差异仅为数值变化,未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase II, randomized VOLFI (AIO-KRK 0109) trial evaluated mFOLFOXIRI + panitumumab compared to FOLFOXIRI in untreated RAS wild type (WT) metastatic colorectal cancer (mCRC). Anti-EGFR antibodies like panitumumab are associated with a specific toxicity profile including skin toxicity, potentially compromising health-related quality of life (HRQoL). METHODS: HRQoL of patients treated in the VOLFI trial was measured using EORTC QLQ-C30 questionnaires. We analyzed HRQoL of patients from the intention-to-treat (ITT) population who completed at least one EORTC QLQ-C30. HRQoL was assessed at baseline and after 6, 12, 18, 24 weeks and completion of treatment. RESULTS: 105 patients were randomized 2:1 to the mFOLFOXIRI + panitumumab and FOLFOXIRI arms. 63 and 33 patients were included in the ITT population, respectively. 77 patients (51 receiving mFOLFOXIRI + panitumumab, 26 receiving FOLFOXIRI) were available for HRQoL assessment. There were no statistically significant differences in overall HRQoL or specific HRQoL dimensions between treatment arms at baseline and after 12 weeks of treatment. Patients receiving mFOLFOXIRI + panitumumab had numerically worsened pain scores and improved social functioning during treatment. In patients receiving mFOLFOXIRI + panitumumab who experienced skin toxicity, overall HRQoL was not associated with the grade of skin toxicity. CONCLUSION: The use of mFOLFOXIRI + panitumumab demonstrated efficacy in first line treatment of RAS WT mCRC compared to FOLFOXIRI without negatively affecting HRQoL. The option to use mFOLFOXIRI plus EGFR-antibodies should primarily be based on physical fitness to receive triplet chemotherapy and to a lesser extent on concerns regarding HRQoL. TRIAL REGISTRATION: ClinicalTrials.gov NCT01328171.
引用
- Klingler TM, Martens UM, Riera-Knorrenschild J, et al. Quality of life in patients with RAS wild-type metastatic colorectal cancer treated mFOLFOXIRI + panitumumab versus FOLFOXIRI: A prespecified secondary analysis of the phase II VOLFI AIO-KRK 0109 trial. Eur J Cancer. 2026. PMID: 42743885. doi:10.1016/j.ejca.2026.117045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。